Last week's blue wave isn't upending health tech investors' strategies, but it is shifting their policy priorities.
Why it matters: "Medicare for All" remains a long shot (despite growing support from Americans) — but PBM reform, permanent telehealth flexibilities and tighter state oversight could gain momentum.
